JP2024542212A5 - - Google Patents
Info
- Publication number
- JP2024542212A5 JP2024542212A5 JP2024529599A JP2024529599A JP2024542212A5 JP 2024542212 A5 JP2024542212 A5 JP 2024542212A5 JP 2024529599 A JP2024529599 A JP 2024529599A JP 2024529599 A JP2024529599 A JP 2024529599A JP 2024542212 A5 JP2024542212 A5 JP 2024542212A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound according
- cancer
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163280409P | 2021-11-17 | 2021-11-17 | |
| US63/280,409 | 2021-11-17 | ||
| PCT/US2022/079973 WO2023091957A1 (en) | 2021-11-17 | 2022-11-16 | Peptide conjugates of peptidic tubulin inhibitors as therapeutics |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024542212A JP2024542212A (ja) | 2024-11-13 |
| JP2024542212A5 true JP2024542212A5 (cg-RX-API-DMAC7.html) | 2025-11-25 |
Family
ID=84799580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024529599A Pending JP2024542212A (ja) | 2021-11-17 | 2022-11-16 | 治療薬としてのペプチドチューブリン阻害剤のペプチドコンジュゲート |
Country Status (14)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022000449A (es) | 2019-07-10 | 2022-04-25 | Cybrexa 2 Inc | Conjugados peptídicos de citotoxinas como terapéuticos. |
| BR112022000297A2 (pt) | 2019-07-10 | 2022-03-15 | Cybrexa 3 Inc | Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006078816A2 (en) * | 2005-01-18 | 2006-07-27 | The Board Of Governors For Higher Education | Selective delivery of molecules into cells or marking of cells in diseased tissue regions using environmentally senstive transmembrane peptide |
| EP2927227A4 (en) * | 2013-01-03 | 2015-12-30 | Celltrion Inc | ANTIBODY CONCENTRATOR REMEDY CONJUGATE, METHOD OF MANUFACTURING THEREOF, AND ANTIBODY TOGETHER THEREWITH |
| WO2018023098A1 (en) * | 2016-07-29 | 2018-02-01 | Memorial Sloan Kettering Cancer Center | Radiolabeled ligands for targeted pet/spect imaging and methods of their use |
| MX2022000449A (es) * | 2019-07-10 | 2022-04-25 | Cybrexa 2 Inc | Conjugados peptídicos de citotoxinas como terapéuticos. |
| BR112022000297A2 (pt) * | 2019-07-10 | 2022-03-15 | Cybrexa 3 Inc | Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos |
-
2022
- 2022-11-16 AU AU2022390891A patent/AU2022390891A1/en active Pending
- 2022-11-16 EP EP22836006.1A patent/EP4433095A1/en active Pending
- 2022-11-16 CN CN202280089024.1A patent/CN118574642A/zh active Pending
- 2022-11-16 US US18/056,117 patent/US20230416331A1/en active Pending
- 2022-11-16 MX MX2024005938A patent/MX2024005938A/es unknown
- 2022-11-16 CA CA3243300A patent/CA3243300A1/en active Pending
- 2022-11-16 WO PCT/US2022/079973 patent/WO2023091957A1/en not_active Ceased
- 2022-11-16 JP JP2024529599A patent/JP2024542212A/ja active Pending
- 2022-11-16 TW TW111143837A patent/TW202330015A/zh unknown
- 2022-11-16 IL IL312884A patent/IL312884A/en unknown
- 2022-11-16 PE PE2024001102A patent/PE20242180A1/es unknown
- 2022-11-16 KR KR1020247020055A patent/KR20240130157A/ko active Pending
-
2024
- 2024-05-16 CL CL2024001486A patent/CL2024001486A1/es unknown
- 2024-06-13 CO CONC2024/0007413A patent/CO2024007413A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019350592B2 (en) | Process of manufacture of a compound for inhibiting the activity of SHP2 | |
| JP6784348B2 (ja) | Ｓｔｉｎｇ作動化合物 | |
| ES2968669T3 (es) | Inhibidores selectivos del inflamasoma NLRP3 | |
| ES2645973T3 (es) | Compuestos y composiciones para modular la actividad del EGFR | |
| ES2693368T3 (es) | Derivados de dolastatina 10 y auristatinas | |
| JP2006507254A5 (cg-RX-API-DMAC7.html) | ||
| ES2660215T3 (es) | Potenciador de efecto antitumoral que comprende un compuesto de imidazooxazina | |
| US11021468B2 (en) | TGF-ß inhibitors | |
| WO1988007045A1 (fr) | Derives de la substance physiologiquement active k-252 | |
| CN107922388A (zh) | 用于抑制shp2活性的化合物和组合物 | |
| ES2280040T3 (es) | Compuestos de tetrahidrobenzotienopirimidinamina sustituidos utiles para tratar trastornos hiperproliferativos. | |
| CN113631228B (zh) | 作为sting激动剂的大环化合物 | |
| WO2022166570A1 (zh) | 同时诱导egfr和parp蛋白降解的化合物及制备方法和应用 | |
| ES2918924T3 (es) | Inhibidores de TGF-beta | |
| CN103826641A (zh) | 作为蛋白激酶抑制剂的含磷化合物 | |
| SA04250095A (ar) | مركبات كيميائية | |
| JP2022541747A5 (cg-RX-API-DMAC7.html) | ||
| AU2020374208B2 (en) | Novel compound and pharmaceutical composition for prevention or treatment of cancer comprising same | |
| JP2018052817A (ja) | 新規ベンズイミダゾール誘導体およびその医薬用途 | |
| CN107011358A (zh) | 新的烷化剂 | |
| CN103613591B (zh) | 作为cMet抑制剂的化合物及其制备方法和用途 | |
| JP2016532714A5 (cg-RX-API-DMAC7.html) | ||
| CN106456613A (zh) | 制备环缩肽的方法 | |
| JP2022538076A5 (cg-RX-API-DMAC7.html) | ||
| CN105164138A (zh) | 新吗啉基蒽环类抗生素衍生物 |